Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00262470 · ClinicalTrials.gov registry record · Phase 1

Treatment of Orthostatic Intolerance

A Phase 1 study of Tachycardia and Chronic Orthostatic Intolerance, sponsored by Satish R. Raj.

Active
Registry status
Phase 1
Development phase
150
Enrollment target
1
Study location

NCT00262470 is a Phase 1 study of Tachycardia and Chronic Orthostatic Intolerance that is active but no longer recruiting, run by Satish R. Raj. The registered enrollment target is 150 participants, below the 880-participant average among 8 other Tachycardia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00262470, a Phase 1 study of Tachycardia and Chronic Orthostatic Intolerance, is active but no longer recruiting, sponsored by Satish R. Raj.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder.

Interventions

  • DRUG Acetazolamide
  • DRUG Atomoxetine
  • DRUG Clonidine
  • OTHER NO Drug
  • DRUG Entacapone

Study Locations (1)

Tennessee

  • Vanderbilt University Autonomic Dysfunction Center - Nashville

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 1997-04
Est. Completion 2029-12
Phase Phase 1

Sponsor

Satish R. Raj

7 total trials

What the Registry Record Tells You About NCT00262470

The ClinicalTrials.gov registry entry for NCT00262470 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 880-participant average among 8 other Tachycardia trials with a reported enrollment target (83% lower). The listed sponsor is Satish R. Raj, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Tachycardia appearing as the primary indexed condition, and to 5 interventions - of which Acetazolamide is the first listed.

NCT00262470 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT00262470 about?

NCT00262470 is a clinical study titled "Treatment of Orthostatic Intolerance". This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder.

What is the current status of trial NCT00262470?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 1997-04. Estimated completion is 2029-12.

What conditions does trial NCT00262470 study?

This clinical trial studies the following conditions: Tachycardia, Chronic Orthostatic Intolerance.

What interventions are being tested in trial NCT00262470?

The interventions under investigation include: Acetazolamide (DRUG), Atomoxetine (DRUG), Clonidine (DRUG), NO Drug (OTHER), Entacapone (DRUG).

Who is sponsoring clinical trial NCT00262470?

This trial is sponsored by Satish R. Raj, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00262470 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tachycardia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.